Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference
Forward-Looking Statements
Some statements in this presentation may be forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding
our investment in high growth emerging markets and development of new products, applications and
technologies, our new focus on lab to clinic solutions, improvements to our operational efficiency, growth
of markets and demand for products, and our future financial performance. Forward-looking statements
generally can be identified by the use of forward-looking terminology such as, “anticipate,” “believe,”
“expect,” “assume,” “continue,” “may,” “will,” “intend,” “estimate,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking statements contain these words. These
statements are subject to risks, uncertainties and other factors that could cause actual results to differ
materially from our expectations. Such factors include, but are not limited to, recent changes to our
global organizational structure and executive management team, difficulties in implementing our global
ERP system, our ability to develop and market new or improved products according to our business
plan, currency fluctuations and other factors discussed in more detail in our recent filings with the
Securities and Exchange Commission. The forward-looking statements contained in this presentation
reflect our views and assumptions only as of the date of this presentation. We do not undertake any
obligation to publicly update any forward-looking statements.
Advance discovery. Improve lives.
Bio-Rad Today
Continuous Innovation
A History of Contribution
8,300+ Employees Worldwide
65+ Years Strong Performance
$2.2B+ Annual Sales
Key Competencies Fueling Ongoing Growth
Complementary
Business Mix Leveraging Across the Company
Advance discovery. Improve lives.
Bio-Rad Global Profile
BioPharma
11%
Reference Labs
13%
Transfusion Labs
12%
Academic
23%
Applied
3%
Hospital Labs
38%
Americas
44%
EMEA
35%
Asia
21%
Diversified Customer Base Worldwide Presence Broad Product Base
Customers Geography Products
Advance discovery. Improve lives.
A History of Innovation
1972
Electrophoresis grade
chemicals are
introduced
2000
Launched the first 4-
color real time PCR
platform on the market
2017
Bio-Rad launches the
first digital PCR CE-IVD
test to monitor levels of
BCR-ABL in cancer
2012
Bio-Rad launches the
droplet digital PCR
system
1967: Bio-Rad launches first T-4
by column test revolutionizing
Thyroid testing
1982: First commercial
test for Hemoglobin A1c
2006: Place first
multiplex immunoassay
system BioPlex 2200
Advance discovery. Improve lives.
Leadership Positions
DNA amplification
Gel image
Protein Assay Quality Control
Blood Typing
Bio-Chromatography
Infectious Disease
Diabetes
Autoimmune
Digital Biology
Electrophoresis
Advance discovery. Improve lives.
Market Focus
7
Bio-Rad is Well-Positioned in New Focus on Lab to Clinic Solutions
Translational Research Continuum
Discovery Development Production Treatment & follow up
• Basic disease
mechanism
research
• Pathway research
• Target
identification
• Target validation
• Lead development
of a therapy and/or
diagnostics
• Pre-clinical studies
• Clinical studies
• Regulatory
• Drug and/or
diagnostics mfg. &
commercialization
• Treatment
planning and
monitoring
• Post-market
surveillance
- Bio-Rad Confidential - Advance discovery. Improve lives.
Genomics, Cell Biology, Proteomic, Software & Informatics
8
Life Science Profile
Asia
26% Americas
43%
EMEA
31%
Consumables
48%
Instruments/ Apparatus
52%
Applied Markets
7% Research
63%
BioPharma
30%
Highlights
Market Size: $45B–50B
Market Growth 4% CAGR
Addressable Market: $8–9B
Source: Bio-Rad Internal
Customer Segments
Revenue Geography
Products
Advance discovery. Improve lives.
9
Life Science Solutions
Genotyping & Gene
Expression
(PCR & qPCR)
Protein Purification
(chromatography)
Gene Transfer
& Modulation
Protein Expression
(multi-analyte detection)
Cellular
Imaging
Protein Quantification
(western blotting)
Antibodies Cell Sorting & Analysis
Multi-omics Solutions
Digital Biology
(Droplet Digital PCR, ddSeq)
Advance discovery. Improve lives.
10
Cell Biology
New Entrant in Growing Market
Flow Cytometry Cell Sorters and Analyzers
Cell Imagers and Counters
Flow Cytometry Reagents & Assays
Flow Cytometry Antibodies
ZOE Fluorescent Cell Imager ZE5 Cell Analyzer
TC20 Automated
Cell Counter
S3e Cell Sorter
Flow
Cytometry
Antibodies
Advance discovery. Improve lives.
Digital Biology
Leadership Position
• ddPCR technology
• Broad IP portfolio
• Broad application from
research to therapeutics
• Rapid development of
new applications
Advance discovery. Improve lives.
12
Clinical Diagnostics Profile
Highlights
Market Size: $55-60B
Addressable Market: $5.5B
Market Growth ~ 5%
Transfusion Laboratory
18%
Customer Segments Hospital
Laboratory
61%
Source: Bio-Rad Internal
EMEA
39%
Americas
42%
Asia
19%
Revenue Geography
Instruments
25%
Reagents
75%
Products
Reference Laboratory
21%
Advance discovery. Improve lives.
13
Clinical Diagnostics
Blood Typing
Blood Virus Screening
HIV Confirmation Testing
Protecting the Blood Supply
Diagnostic Testing and Monitoring
Diabetes
Infectious Disease
Autoimmune
Transfusion Compatibility
Quality Controls
Quality Assessments
Data Management
Quality Assurance
Advance discovery. Improve lives.
14
Highlights
Bio-Rad #2 in Market
3,000+ Automated Systems Placed
Unrivalled Results Management
Broadest portfolio for safe transfusions
Geographic Expansion
IH-1000 and IH-500 FDA Approvals
IH-Com and Manual Systems Approval
Growing Demand in Emerging Markets
Blood Typing
IH-500
Tango infinity
IH-1000
Gel Cards
IH-Com & IH-Web
Results Management
Advance discovery. Improve lives.
Portfolio Expansion
Near Term Focus
• Core Market Enhancement
• Microbiome
• Point of Care
• Non-Invasive Prenatal Testing
Advance discovery. Improve lives.
16
The Importance Of Clinical Diagnostics In Healthcare
Earlier detection saves lives
• Lowers total costs
• Reduces risks
• Increases satisfaction
• Improves treatment efficiency
Targeted Disease Prevention
Early Disease Detection
Accelerated Diagnostics
Targeted Therapy
Improved
Outcomes
Advance discovery. Improve lives.
17
Diabetes
Diabetes is an accelerating global problem.
Advance discovery. Improve lives.
18
Bio-Rad Pioneered HbA1c Testing
Bio-Rad provides HbA1c testing solutions for all segments,
leading to better outcomes for patients with diabetes.
Small Labs /
Clinics
Medium Labs Large Labs
D-10 VARIANT II D-100
Advance discovery. Improve lives.
19
Cancer
The global cancer burden continues to rise, with 18 million
new cases and over 9 million deaths in 2018.
Early Detection Is Key To Survival
* Cancer Research UK Advance discovery. Improve lives.
20
Bio-Rad Is Pioneering Digital PCR In Liquid Biopsy
Systems Consumables Menu
For customers developing
and validating tests Droplet digital PCR
platforms
Large portfolio of assays
Bio-Rad products enable monitoring of a patient’s response
to targeted therapy.
Advance discovery. Improve lives.
Discovery
Development Therapies
Translational Discovery to Diagnostics
Advance discovery. Improve lives.
Target validation
Lead development of a
therapy and/or diagnostics
Pre-clinical studies
Basic disease mechanism research
Pathway research
Target identification
Treatment planning
and monitoring
Post-market surveillance
Clinical studies
Regulatory
Drug and/or diagnostics
manufacturing and
commercialization
Production
Translational
Medicine
Operational Transformation
Advance discovery. Improve lives.
Building a Scalable Model
23
The Opportunity
Increase visibility
Optimize inventory levels
Improve service
Reduce scrap
Lower project overhead
Leverage
ERP Investment
Rationalize
Global Footprint
Consolidate distribution
centers
Close redundant
commercial sites
Increase Asia
manufacturing
Manage
Procurement
Centralized Procurement
Global price concessions
Targeted reduction in
direct and indirect
purchases
Advance discovery. Improve lives.
24 Advance discovery. Improve lives.
Creating Shareholder
Value
Accelerating Free Cash
Flow
Driving Revenue Growth
Expanding EBITDA Margins
The Path Forward
Increased Cash Flow
Disciplined Capital
Allocation
Geographic Expansion
New Products
New Markets
Higher Profitability
Reduced CAPEX
Tax Savings
Optimized Supply Chain
Reduced ERP Spend
Shared Services
Operating Leverage
Key Contributions to Value Creation
Summary – Closing Remarks
Investments at an inflection point
Building on our market and product leadership
Increased focus on acquisition opportunities
Leveraging our new organization, operating model and
systems to drive value
Advance discovery. Improve lives.
Bio-Rad Laboratories, Inc. Jefferies 2019 Healthcare Conference